Country: United States
Language: English
Source: NLM (National Library of Medicine)
Milrinone lactate (UNII: 9K8XR81MO8) (Milrinone - UNII:JU9YAX04C7), Dextrose monohydrate (UNII: LX22YL083G) (Dextrose - UNII:IY9XDZ35W2)
B. Braun Medical Inc.
Milrinone Lactate and Dextrose monohydrate
INJECTION
200 ug in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Milrinone Lactate in 5% Dextrose Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. Milrinone Lactate in 5% Dextrose Injection is contraindicated in patients who are hypersensitive to milrinone. Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
Milrinone Lactate 20 mg (base)/100 mL (200 mcg (0.2 mg)[base]/mL) in 5% Dextrose Injection is supplied sterile and nonpyrogenic in 100 mL fill PAB® plastic containers packaged 4 per carton, 6 cartons per case (24 per case). Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Store the individual container in the storage carton until ready to use.
MILRINONE LACTATE IN DEXTROSE- MILRINONE LACTATE AND DEXTROSE MONOHYDRATE INJECTION B. BRAUN MEDICAL INC. ---------- SINGLE DOSE PAB PLASTIC CONTAINER FOR INTRAVENOUS INFUSION ONLY. DESCRIPTION Milrinone Lactate in 5% Dextrose Injection is a sterile, aqueous solution of milrinone in 5% dextrose. It is administered by the intravenous route. It is premixed and requires no further dilution. Milrinone is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile lactate. Milrinone is an off-white to tan crystalline compound with a molecular formula of C H N O. It is slightly soluble in methanol, and very slightly soluble in chloroform and in water. As the lactate salt, it is stable and colorless to pale yellow in solution. The molecular structures of milrinone lactate and dextrose (hydrous) are as follows: The PAB Container is Latex-free, PVC-free, and DEHP-free. The PAB plastic container system provides a ready-to-use dilution of milrinone in a volume of 100 mL of 5% Dextrose Injection. Each mL contains milrinone lactate equivalent to 200 mcg milrinone. The nominal concentration of Lactic Acid USP is 0.282 mg/mL. Each mL also contains 49.4 mg Dextrose, Anhydrous, USP in Water for Injection, USP. The pH is adjusted to between 3.2 and 4.0 with lactic acid and/or sodium hydroxide. The solution contains no preservative and is intended only for use as a single-dose injection. When smaller doses are required the unused portion should be discarded. The PAB plastic container system is a copolymer of ethylene and propylene formulated and developed for parenteral drugs. The copolymer contains no plasticizers and exhibits virtually no leachability. The safety of the plastic container has been confirmed by biological evaluation procedures. The material passes Class Vl testing as specified in the U.S. Pharmacopeia for Bio Read the complete document